Gorjan Hrustanovic, PhD is a Partner at BVF Partners, where he is responsible for overseeing biotech investments for both private and public companies. Dr. Hrustanovic currently serves on the board of directors of Olema Pharmaceuticals, Kymera Therapeutics, Forward Therapeutics, Plexium, and also served on Board of Nimbus Therapeutics and Rain Therapeutics.
Prior to joining BVF in 2015, Dr. Hrustanovic obtained his PhD in cancer biology and cell signaling at the University of California, San Francisco (UCSF), with a primary focus on precision medicine and resistance to targeted therapies in lung cancer. His graduate research led to publications in leading scientific journals such as Nature Medicine and others. Dr. Hrustanovic earned a BS degree in molecular biology, and a BS in economics and management science from the University of California, San Diego.
